Invuity (NASDAQ: IVTY) and Ekso Bionics Holdings (NASDAQ:EKSO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Valuation & Earnings

This table compares Invuity and Ekso Bionics Holdings’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Invuity $36.63 million 3.72 -$35.61 million ($2.51) -3.19
Ekso Bionics Holdings $7.49 million 3.96 -$27.14 million ($1.55) -0.74

Ekso Bionics Holdings has higher revenue, but lower earnings than Invuity. Invuity is trading at a lower price-to-earnings ratio than Ekso Bionics Holdings, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Invuity and Ekso Bionics Holdings’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Invuity -114.61% -140.69% -68.16%
Ekso Bionics Holdings -372.20% -798.93% -146.30%

Analyst Ratings

This is a summary of recent ratings and price targets for Invuity and Ekso Bionics Holdings, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Invuity 0 0 5 0 3.00
Ekso Bionics Holdings 0 0 2 0 3.00

Invuity presently has a consensus target price of $12.75, suggesting a potential upside of 59.38%. Ekso Bionics Holdings has a consensus target price of $6.00, suggesting a potential upside of 421.74%. Given Ekso Bionics Holdings’ higher possible upside, analysts clearly believe Ekso Bionics Holdings is more favorable than Invuity.

Institutional and Insider Ownership

68.3% of Invuity shares are owned by institutional investors. Comparatively, 6.0% of Ekso Bionics Holdings shares are owned by institutional investors. 10.5% of Invuity shares are owned by company insiders. Comparatively, 7.1% of Ekso Bionics Holdings shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Invuity has a beta of -0.13, meaning that its stock price is 113% less volatile than the S&P 500. Comparatively, Ekso Bionics Holdings has a beta of -0.93, meaning that its stock price is 193% less volatile than the S&P 500.

Summary

Invuity beats Ekso Bionics Holdings on 8 of the 12 factors compared between the two stocks.

Invuity Company Profile

Invuity, Inc., a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges. It offers various illuminated surgical devices, including Eikon LT Illuminated and Eikon illuminated retractor systems for breast oncology/oncoplastic/general/orthopedics surgeries; Saber Yankauer, a handheld illuminator for orthopedic/spine/cardiothoracic/breast/general surgeries; and Saber Frazier, a handheld illuminator for spine/orthopedic/neurosurgery surgeries. The company also provides Eika illuminated retractor systems for anterior neck approaches comprising thyroid and cervical spine surgeries; Breiten illuminated retractor systems for spine surgeries; Eipex illuminated retractor systems for spine/orthopedic surgeries; Eivector illuminated and Eiberg Illuminated retractor systems for orthopedic surgeries; and Waveguide XT system, a drop-in intracavity illuminator for spine surgeries. Invuity, Inc. sells its devices through its direct sales representatives and independent sales agents; and directly to hospitals and surgeons, as well as to third-party medical device manufacturers. The company was formerly known as Spotlight Surgical, Inc. and changed its name to Invuity, Inc. in 2007. Invuity, Inc. was incorporated in 2004 and is based in San Francisco, California.

Ekso Bionics Holdings Company Profile

Ekso Bionics Holdings, Inc. designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness. The company’s Ekso device is primarily used in a clinic or rehabilitation setting. It also performs research and development work on human exoskeletons and related technologies. The company has a license agreement with Lockheed Martin Corporation to develop products for military applications, as well as with OttoBock Healthcare Products Gmbh. The company was founded in 2005 and is headquartered in Richmond, California. Ekso Bionics Holdings, Inc. operates as a subsidiary of Magee Rehabilitation Hospital.

Receive News & Stock Ratings for Invuity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity Inc. and related stocks with our FREE daily email newsletter.